Practical aspects of immunoglobulin replacement

Annals of Allergy, Asthma & Immunology

September  2017 Volume 119, Issue 4, Pages 299-303 MOC-CME Review

Accreditation: The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation: The American College of Allergy, Asthma & Immunology (ACAAI) designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Planning Committee Members:
Mark Ballow, MD (Author)
Jonathan A. Bernstein, MD (CME Subcommittee)
Guha Krishnaswamy, MD (CME Subcommittee)
John J. Oppenheimer, MD (CME Subcommittee, Associate Editor)
Mitchell H. Grayson, MD (CME Series Editor, Deputy Editor)
Gailen D. Marshall, Jr, MD, PhD (Editor-in-Chief)

Target Audience

Physicians involved in providing patient care in the field of allergy/asthma/immunology

Learning Objectives

At the conclusion of this activity, participants should be able to:
Differentiate the advantages and disadvantages of IVIG and SCIg
Discuss the approach to optimizing dosing of immunoglobulin replacement therapy in patients with antibody immune deficiency
Describe the guiding principles for the effective use of immunoglobulin replacement therapy in patients with antibody immune deficiency

Additional information
Disclosure: 

Any unapproved/investigative uses of therapeutic agents/devices discussed are appropriately noted. M. Ballow – Advisory Board member for Shire, and Grifols and Speaker for Shire, he received fees; he has received research grants from CSL Behring and Grifols; J.A. Bernstein – PI, Consultant, Speaker for AstraZeneca, CSL Behring, Novartis/Genentech, and Shire, he received research grants and fees; Speaker for Baxalta, he received fees; Consultant for Imedics, he received fees; PI and Consultant for Boehringer Ingelheim and GlaxoSmithKline, he received research grants and fees. G. Krishnaswamy – Clinical Research for CSL Behring, he received a research grant; J. Oppenheimer – Consultant for DBV Technologies, GlaxoSmithKline, and Kaleo, he received other financial gains; Clinical research for AstraZeneca, Boehringer Ingelheim, and Novartis, he received research grants. M.H. Grayson – Clinical research for Polyphor, Ltd., he received a research grant. G.D. Marshall – Clinical Research for Stallergens and Sanofi, he received research grants.

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Course opens: 
10/01/2017
Course expires: 
09/30/2019
Cost:
$0.00
Rating: 
0

Planning Committee Members:
Mark Ballow, MD (Author)
Jonathan A. Bernstein, MD (Annals CME Subcommittee)
Guha Krishnaswamy, MD (Annals CME Subcommittee)
John J. Oppenheimer, MD (CME Subcommittee, Associate Editor)
Mitchell H. Grayson, MD (CME Series Editor, Deputy Editor)
Gailen D. Marshall, Jr, MD, PhD (Editor-in-Chief)

Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance

Accreditation Period

Course opens: 
10/01/2017
Course expires: 
09/30/2019

Price

Cost:
$0.00
Please login or create an account to take this course.